Navigation Links
Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
Date:5/4/2009

Changes Will Result in a 35% Sales Force Reduction and Approximately $45 Million Annual GAAP Operating Results Benefit

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced a new approach to sales within the diabetes market. Amylin's existing primary care and specialty sales forces will merge into a single organization that brings a specialty approach to endocrinologists and diabetes-focused primary care physicians. The changes are expected to be implemented in the next several weeks and will reduce the total number of Amylin sales representatives by approximately 35 percent, or 200 employees, and will result in an annualized benefit of approximately $45 million to GAAP operating results in 2010.

The new sales approach is part of Amylin's continuing efforts to improve the efficiency and effectiveness of exenatide alliance operations with partner Eli Lilly and Company, and to maximize the value of the Company's current and future portfolio of first-in-class diabetes products. The changes to Amylin's field sales organization will be coordinated and aligned with the continuing exenatide sales efforts of Lilly. Amylin's resulting field sales organization will include approximately 325 sales representatives focused on endocrinologists and other physicians that treat significant numbers of diabetes patients. Lilly will continue their efforts within the endocrinology and larger primary care prescriber market to support BYETTA(R) (exenatide) injection. Overall, these changes will better position the companies for the anticipated launch of exenatide once weekly.

"This new, more focused approach to sales optimizes Amylin's sales organization for our portfolio today and in the future, and will enable us to improve the quality of our interactions with core prescribers through m
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Woo Young Lee of the Chemical Engineering and ... of Chemistry, Chemical Biology and Biomedical Engineering at ... NSF funding for their research entitled, "Evaporative Assembly ... is a reflection of the pioneering work being ...
... 20 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or ... that its Special Meeting of Shareholders held today, its shareholders, ... excluding Mr. Han, voted to approve the merger of Datong ... to the Agreement and Plan of Merger dated March ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing ... entered into a purchase agreement to sell $3.9 million of ... registered public offering.   , , ... Under the terms of the purchase agreement, PharmAthene will sell an aggregate ...
Cached Biology Technology:NSF funds infection-resistant orthopedic research 2Dragon Pharma shareholders approve merger and seek termination of listing on the OTCBB and TSX 2PharmAthene Announces $3.9 Million Registered Direct Offering 2PharmAthene Announces $3.9 Million Registered Direct Offering 3
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... about one per eight hundred births, Down syndrome - ... cause of intellectual disability. It results from a chromosomal ... copy of chromosome 21 (1% of the human genome). ... in the Department of Genetic Medicine and Development at ... in Nature , shed light on how the ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... African-American women who get breast cancer often get more aggressive ... women. But a Georgia State University researcher has found ... which would let their doctors customize their treatment. Ritu ... called HSET. Earlier studies have linked elevated levels of HSET ...
... 2013  DigitalPersona, Inc., a trusted partner for biometric ... ® FingerJet ® Recognition Engine matching ... of Standards and Technology (NIST) and the MINEX ... States Government,s  Personal Identity Verification (PIV) standards.  ...
... Dec. 10, 2013 Kurt H. Becker , the ... at the Polytechnic Institute of New York University (NYU-Poly), has ... Inventors (NAI).  Becker was chosen by ... facilitating outstanding inventions that have made a tangible impact on ...
Cached Biology News:DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 3
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains, Aga1 and Aga2, to display recombinant ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
Biology Products: